TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Participants With Abnormal Laboratory Parameter Values (Hematology)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Abnormal Laboratory Parameter Values (Chemistry)
Endpoint domain: Adverse events/effects
Primary endpoint: Patient's response to antipsychotic drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrolyte disturbances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adipose Cell Size Distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Feasibility of participant recruitment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Liver Fat Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma Triglyceride (TG) Area Under Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time-to-Rehospitalization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Achieving Low Disease Activity (LDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Boston Carpal Tunnel Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in conditioned pain modulation (CPM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in The HERO Wellness Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Functional capacity of the lower limb muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Safety of vismodegib in combination with temozolomide
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of vismodegib in combination with temozolomide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: HPV Vaccine Uptake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: realization of a full digital rectal examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Drug exposure (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of decline of viable M.tubercolosis in sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Collecting adverse events as a measure of safety
Endpoint domain: Adverse events/effects
Primary endpoint: Ratio of mature LB subpopulations and memory LB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokine analysis (IL10, alpha-TNF, gamma-IFN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to Union
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Union-rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: feasibility of accelerometer-based assessment of physical activity (recruitment rate)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: self-efficacy to comply
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cumulative One-year Acute Rejection Rates
Endpoint domain: Mortality/survival
Primary endpoint: One-year Graft Survival
Endpoint domain: Mortality/survival
Primary endpoint: One-year Patient Survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in sensory function in upper limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Cardiopulmonary Fitness Level From Baseline to the Window Following Chemotherapy Completion and Before Surgical Resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Levels of COPD self-management behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Levels of COPD psychological resilience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of subjects reporting at least 1 serious adverse event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects prematurely discontinuing due to a treatment emergent adverse event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of ABI-011
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profile of TMC435350
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profile of rifampin and 25-deacetylrifampin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: minimum saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: degree of sleep apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serum concentration of creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Serum concentration of cystatin C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urine concentration of Albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from baseline in daytime sleepiness (ESS score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resolution of abnormal fetal heart tracing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of lymphoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area under the curve of midazolam (AUC12h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Cases of Influenza
Endpoint domain: Adverse events/effects
Primary endpoint: Progressive Supranuclear Palsy Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in Pore number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective evaluations for improvement in appearance of facial pores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction evaluations for treatment results
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: T-cell profile in visceral and subcutaneous fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adipose cell size associated with T cell profile and IR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Macrophage phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of recurrence at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Luminosity on ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in mean change of systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in a fidelity summary score for key implementation strategy components
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: loco-regional recurrence free survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in Physical Activity-Active Minutes/Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Physical Activity-Steps/Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual rotational laxity during MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mesial-distal (M-D) bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Initial voriconazole trough plasma concentration in the therapeutic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of the epidemiology of Spondyloarthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Curve progression (Cobb)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Curve progression (Bracing)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hot Flash intensity/bother
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Alcoholic Drinks Consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Multiple Organ Failure (MOF) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incremental physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Profile of circulating microRNAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in ADAS-Cog14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum severity of cyclic breast pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Visual acuity values concordance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bSG patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Death Attributable to Complications of Protocol Therapy
Endpoint domain: Mortality/survival
Primary endpoint: Acute Rejection at 6-Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum tolerated dose of riluzole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sweetened beverages purchased
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: hot flash composite and frequency scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of clinician-rated adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in plasma endotoxin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Presence of fragmented QRS complex and prolonged QT interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Amplitude of alpha oscillations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attendance to Lung Health Check Appointment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average number of potentially inappropriate medications (PIMs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Occurrence of SALD
Endpoint domain: Adverse events/effects
Primary endpoint: Total volume of contrast administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Challenging behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombotic and Hemorrhagic Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Hemophilia Joint Health Score (HJHS) 2.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Independence Score in Hemophilia (FISH)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total Number of Index Joint Bleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life deficits
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adolescents' symptoms of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adolescents' symptoms of depression and anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of atazanavir, dolutegravir and lamivudine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the IRLS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of binary angiographic in-stent restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with healed corneal ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Instructor satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of Patients With Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: CHD Death
Endpoint domain: Mortality/survival
Primary endpoint: Severe Acute Kidney Injury (AKI) requiring Continuous Renal Replacement Therapy (CRRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Inflammation in the anterior chamber after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in macular thickness and occurrence of Cystoid macular edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Significant relief of severity and pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant relief of severity by objective kinematic reductions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time Until Hospital Discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: predictive powers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse/Progression Rate
Endpoint domain: Mortality/survival
Primary endpoint: Fugl-Meyer Upper Extremity Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious Adverse Device Effect (SADE) -free rate
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in atrial and ventricular pacing threshold(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in P-wave and R-wave amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Observational learning ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rule-based learning ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prevalence of HLA-B*5701
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Patients That Experience 10% Decline in Triglycerides From Baseline to Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: At Week 24 the Percentage of Subjects That Had Triglycerides Less Than 200 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: The Change in Fasting Triglyceride Level From Baseline to Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short-term impact of the program
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between plasma concentration and anticoagulant effect of dabigatran
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammation-endothelial-dysfunction index (IEDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of newly diagnosed hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients with undetectable HIV RNA viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety event frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Middle molecular weight molecules clearances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Function subscale score of the WOMAC
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: ADAS-Cog Delayed Word Recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: C1-esterase Inhibitor Functional Activity Trough Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adipose Cell Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency and severity of intrusive memories
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients converting to undetectable minimal residual disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic sample collection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CSF p-tau181
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage visiting the Internet site
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Work capacity index (CRE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Volumetric Bone Mineral Density (vBMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Seattle Angina Questionnaire (SAQ) Summary Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of SAH patients with DCI in whom the intervention was adequately performed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Treatment-related Mortality (TRM)
Endpoint domain: Mortality/survival
Primary endpoint: Histology-determined fibrosis stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total and Surgical Induced Astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant Simulator Attitude Scale (ISA)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Immunogenic profile variations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Phenolic and terpenoid content or metabolites of Mastiha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the curve (AUC0-∞) of TT-00420
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC0-t) of TT-00420
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration (Cmax) of TT-00420
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: left ventricular function (left ventricular ejection fraction and end-diastolic volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Immediate Unsolicited Adverse Events (AEs) After Any Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Serious Adverse Events (SAEs) After Any Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Achieving Seroconversion Against Antigens Following Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in CAV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants attending CBT sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of patients enrolled as per target
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: articulatory motor-evoked potential (aMEP) amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degraded speech comprehension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of reporting cancer overall
Endpoint domain: Mortality/survival
Primary endpoint: Risk of reporting specific cancers
Endpoint domain: Mortality/survival
Primary endpoint: Numeric rating scale pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alleviation of itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood stasis syndrome scale of Coronary heart disease angina pectoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Significant change in pulse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Significant change in systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Significant change in oxygen arterial saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Steady state plasma glucose (SSPG) as a measure of insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of clinically important hypoglycemia (Level 2 hypoglycemia, <54 mg/dL)
Endpoint domain: Adverse events/effects
Primary endpoint: Percent time in clinically important hypoglycemia (Level 2 hypoglycemia, <54 mg/dL)
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Curve (AUC) of FVIII:C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life (h) of FVIII:C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes